J&J COVID-19 vaccine benefits ‘far outweigh’ risks, CDC panel says after reports of Guillain-Barré syndrome - Fox News

An advisory panel to the Centers for Disease Control and Prevention (CDC) said the benefits of COVID-19 vaccines “far outweigh” potential risks amid an ongoing review of reports of a rare ... Read More

CDC, FDA lift pause on Johnson & Johnson vaccine with warning of risks - ABC News

Dr. Tom Shimabukuro, a member of the CDC’s task force on COVID-19 vaccines, told the panel that all of the 15 cases were women.Most of them were in their 30s, although the age range was 18 to 59 ... Read More

CDC safety panel: J&J vaccine benefits outweigh rare neuro risks seen in older adults - McKnight's Long-Term Care News

The benefits of the shot — including reduced hospitalization, intensive care unit admission and death — outweigh the risk of contracting Guillain-Barre syndrome, the Advisory Committee on ... Read More

Benefits of J&J COVID-19 vaccine outweigh risks, CDC says - Becker's Hospital Review

The benefits of Johnson & Johnson's COVID-19 shot still outweigh the risk of the rare but serious neurological disorder, Guillain-Barre syndrome, the CDC said July 22, according to CNBC. Read More

Doctor on CDC Panel Sees ‘Huge Amount of Evidence' That J&J Covid Vaccine Benefits Outweigh Risk - NBC Chicago

A member of a key CDC advisory panel told CNBC on Friday morning that he expects the U.S. pause on Johnson & Johnson's one-dose coronavirus vaccine to eventually be lifted. "I think that there is ... Read More

FDA panel supports a booster for all adults who got J&J COVID vaccine - USA TODAY

For all age groups, vaccine effectiveness is highest in Moderna vaccine recipients, at 95%, followed by Pfizer-BioNTech at 80% and J&J at 60%, a report published by the CDC on Sept. 17 found. Read More